-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 WcxXw2OgZ3AZ9Hb4RjxoZNerrAnag/NrYO7w8oObVJ5gBuYdkXH26hLbDOp+Ey+W
 rz/cbi18JsMQ4eyYdPrf0Q==

<SEC-DOCUMENT>0001157523-09-006356.txt : 20090904
<SEC-HEADER>0001157523-09-006356.hdr.sgml : 20090904
<ACCEPTANCE-DATETIME>20090904163022
ACCESSION NUMBER:		0001157523-09-006356
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20090903
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20090904
DATE AS OF CHANGE:		20090904

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Celldex Therapeutics, Inc.
		CENTRAL INDEX KEY:			0000744218
		STANDARD INDUSTRIAL CLASSIFICATION:	IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
		IRS NUMBER:				133191702
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-15006
		FILM NUMBER:		091056445

	BUSINESS ADDRESS:	
		STREET 1:		119 FOURTH AVE
		CITY:			NEEDHAM
		STATE:			MA
		ZIP:			02494
		BUSINESS PHONE:		7814330771

	MAIL ADDRESS:	
		STREET 1:		119 FOURTH AVE
		CITY:			NEEDHAM
		STATE:			MA
		ZIP:			02494-2725

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AVANT IMMUNOTHERAPEUTICS INC
		DATE OF NAME CHANGE:	19980828

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	T CELL SCIENCES INC
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>a6043347.htm
<DESCRIPTION>CELLDEX THERAPEUTICS, INC. 8-K
<TEXT>
<html>
  <head>
    <title></title>
<!--Copyright 2009 Business Wire, a Berkshire Hathaway company.-->
<!--All rights reserved www.businesswire.com-->
  </head>
  <body style="font-family: Times New Roman; font-size: 10pt">
    <p>

    </p>
    <p style="text-align: center">
      <font style="font-family: Times New Roman; font-size: 10pt">UNITED STATES</font><font style="font-family: Times New Roman; font-size: 10pt"><br style="font-family: Times New Roman; font-size: 10pt"></font><font style="font-family: Times New Roman; font-size: 10pt">SECURITIES
      AND EXCHANGE COMMISSION</font><font style="font-size: 10pt"><br style="font-size: 10pt"></font><font style="font-family: Times New Roman; font-size: 10pt">WASHINGTON,
      D.C. 20549</font><font style="font-size: 10pt"><br style="font-size: 10pt"></font><font style="font-size: 10pt"><br style="font-size: 10pt"></font><font style="font-family: Times New Roman; font-size: 10pt"><b>FORM
      8-K</b></font><font style="font-size: 10pt"><br style="font-size: 10pt"></font><br>CURRENT
      REPORT<br><font style="font-size: 10pt"><br style="font-size: 10pt"></font><font style="font-family: Times New Roman; font-size: 10pt">PURSUANT
      TO SECTION 13 OR 15(d) OF</font><br><font style="font-family: Times New Roman; font-size: 10pt">THE
      SECURITIES EXCHANGE ACT OF 1934</font><font style="font-size: 10pt"><br style="font-size: 10pt"></font><br><br><font style="font-family: Times New Roman; font-size: 10pt">Date
      of Report (Date of earliest event reported): &#160;</font><font style="font-family: Times New Roman; font-size: 10pt"><b>September
      3, 2009</b></font><br><br><font style="font-family: Times New Roman; font-size: 10pt"><b>CELLDEX
      THERAPEUTICS, INC.</b></font><br><font style="font-family: Times New Roman; font-size: 10pt">(Exact
      name of registrant as specified in its charter)</font><br>
    </p>
    <p style="text-align: center">
      <br>

    </p>
    <div style="text-align:left">
    <table style="font-family: Times New Roman; font-size: 10pt; width: 100%; margin-bottom: 10.0px" cellspacing="0">
      <tr>
        <td valign="bottom" style="width: 33%; text-align: center; padding-left: 0.0px">
          <p style="margin-top: 0px; margin-bottom: 0px">
            <b>Delaware</b>
          </p>
        </td>
        <td valign="bottom" style="white-space: nowrap; padding-right: 0.0px; width: 34%; text-align: center; padding-left: 0.0px">
          <p style="margin-top: 0px; margin-bottom: 0px">
            <b>0-15006</b>
          </p>
        </td>
        <td valign="bottom" style="white-space: nowrap; padding-right: 0.0px; width: 33%; text-align: center; padding-left: 0.0px">
          <p style="margin-top: 0px; margin-bottom: 0px">
            <b>13-3191702</b>
          </p>
        </td>
      </tr>
      <tr>
        <td valign="bottom" style="width: 33%; text-align: center; padding-left: 0.0px">
          <p style="margin-top: 0px; margin-bottom: 0px">
            (State or other jurisdiction
          </p>
          <p style="margin-top: 0px; margin-bottom: 0px">
            of incorporation)
          </p>
        </td>
        <td valign="top" style="width: 34%; text-align: center; padding-left: 0.0px">
          <p style="margin-top: 0px; margin-bottom: 0px">
            (Commission File Number)
          </p>
        </td>
        <td valign="top" style="width: 33%; text-align: center; padding-left: 0.0px">
          <p style="margin-top: 0px; margin-bottom: 0px">
            (IRS Employer
          </p>
          <p style="margin-top: 0px; margin-bottom: 0px">
            Identification No.)
          </p>
        </td>
      </tr>
    </table>
    </div>
    <p>
      <br>

    </p>
    <div style="text-align:left">
    <table style="font-family: Times New Roman; font-size: 10pt; width: 100%; margin-bottom: 10.0px" cellspacing="0">
      <tr>
        <td style="width: 25%">
          &#160;
        </td>
        <td valign="bottom" style="width: 50%; text-align: center; padding-left: 0.0px">
          <p style="margin-top: 0px; margin-bottom: 0px">
            <b>119 Fourth Avenue<br>Needham, Massachusetts 02494-2725</b>
          </p>
        </td>
        <td valign="bottom" style="width: 25%; text-align: center; padding-left: 0.0px">
          <p style="margin-top: 0px; margin-bottom: 0px">
            &#160;
          </p>
        </td>
      </tr>
      <tr>
        <td valign="bottom" style="text-align: center; padding-left: 0.0px" colspan="3">
          <p style="margin-top: 0px; margin-bottom: 0px">
            <font style="font-family: Times New Roman; font-size: 10pt">(Address
            of principal executive offices)(Zip Code)</font>
          </p>
        </td>
      </tr>
    </table>
    </div>
    <p style="text-align: center">
      <font style="font-family: Times New Roman; font-size: 10pt"><b>(781)
      433-0771</b></font><font style="font-family: Times New Roman; font-size: 10pt"><br style="font-family: Times New Roman; font-size: 10pt"></font><font style="font-family: Times New Roman; font-size: 10pt">(Registrant&#8217;s
      telephone number, including area code)</font><font style="font-family: Times New Roman; font-size: 10pt"><br style="font-family: Times New Roman; font-size: 10pt"></font>
    </p>
    <p style="text-indent: 30.0px; text-align: left">
      <font style="font-family: Times New Roman; font-size: 10pt">Check the
      appropriate box below if the Form 8-K filing is intended to
      simultaneously satisfy the filing obligation of the registrant under any
      of the following provisions:</font>
    </p>
    <p>
      <font style="font-family: Arial Unicode MS; font-size: 10pt">&#8414;</font><font style="font-family: Times New Roman; font-size: 10pt">
      Written communications pursuant to Rule 425 under the Securities Act (17
      CFR 230.425)</font>
    </p>
    <p>
      <font style="font-family: Arial Unicode MS; font-size: 10pt">&#8414;</font><font style="font-family: Times New Roman; font-size: 10pt">
      Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17
      CFR 240.14a-12)</font>
    </p>
    <p>
      <font style="font-family: Arial Unicode MS; font-size: 10pt">&#8414;</font><font style="font-family: Times New Roman; font-size: 10pt">
      Pre-commencement communications pursuant to Rule 14d-2(b) under the
      Exchange Act (17 CFR 240.14d-2(b))</font>
    </p>
    <p>
      <font style="font-family: Arial Unicode MS; font-size: 10pt">&#8414;</font><font style="font-family: Times New Roman; font-size: 10pt">
      Pre-commencement communications pursuant to Rule 13e-4(c) under the
      Exchange Act (17 CFR 240.13e-4(c))</font>
    </p>
    <p>

    </p>
    <div style="margin-left: 0pt; text-indent: 0pt; margin-right: 0pt; width: 100%; margin-bottom: 10pt">
      <div>
        <div style="text-align: left">

        </div>
      </div>
      <div style="page-break-after: always">
        <div style="text-align: center">

        </div>
        <div style="text-align: center">
          <hr style="color: black; height: 1.5pt">

        </div>
      </div>
      <div>
        <div style="text-align: right">

        </div>
      </div>
    </div>
    <p style="white-space: nowrap; text-align: justify">

    </p>
    <p style="white-space: nowrap; text-align: justify">
      <b>Item 8.01.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Other Events.</b>
    </p>
    <p style="text-align: justify">

    </p>
    <p style="text-align: justify">
      On September 3, 2009, Celldex Therapeutics, Inc. (the &#8220;Company&#8221;)
      announced that, effective that day, Charles R. Schaller has stepped down
      as Chairman of the Board of Directors (the &#8220;Board&#8221;) and Larry Ellberger
      has been appointed to succeed Mr. Schaller as Chairman.&#160;&#160;Mr. Schaller
      will continue to serve as a member of the Board.&#160;&#160;
    </p>
    <p style="text-align: justify">

    </p>
    <p style="text-align: justify">
      The Company also announced that, in connection with Mr. Ellberger's
      appointment as Chairman of the Board, Mr. Ellberger has resigned as
      Chairman of the Audit Committee of the Board and George Elston has been
      appointed his successor.&#160;&#160;Mr. Ellberger will remain a member of the
      Audit Committee.
    </p>
    <p style="text-align: justify">

    </p>
    <p style="text-align: justify">
      A copy of the press release announcing the appointment of Mr. Ellberger
      as Chairman of the Board is attached hereto as Exhibit 99.1 and is
      incorporated herein by reference.
    </p>
    <p style="white-space: nowrap">

    </p>
    <p style="white-space: nowrap">
      <b>Item 9.01. &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Financial Statements and Exhibits.</b>
    </p>
    <p style="white-space: nowrap">

    </p>
    <div style="text-align:left">
    <table style="font-family: Times New Roman; font-size: 10pt; width: 100%; margin-bottom: 10.0px" cellspacing="0">
      <tr>
        <td valign="middle" style="width: 12%; text-align: center; border-bottom: solid black 1.0pt; padding-left: 0.0px">
          <p style="margin-top: 0px; margin-bottom: 0px">
            <b>Exhibit</b>
          </p>
        </td>
        <td valign="middle" style="padding-bottom: 2.0px; width: 3%; text-align: left; padding-left: 0.0px">
          &#160;
        </td>
        <td valign="middle" style="width: 85%; text-align: left; border-bottom: solid black 1.0pt; padding-left: 0.0px">
          <p style="margin-top: 0px; margin-bottom: 0px">
            <b>Description</b>
          </p>
        </td>
      </tr>
      <tr>
        <td valign="top" style="width: 12%; text-align: left; padding-left: 0.0px">
          <p style="margin-top: 0px; margin-bottom: 0px">
            Exhibit 99.1
          </p>
        </td>
        <td style="width: 3%">

        </td>
        <td valign="top" style="width: 85%; text-align: left; padding-left: 0.0px">
          <p style="margin-top: 0px; margin-bottom: 0px">
            Press release issued by Celldex Therapeutics, Inc. announcing
            appointment of Larry Ellberger as Chairman of the Board.
          </p>
        </td>
      </tr>
    </table>
    </div>
    <p>

    </p>
    <div style="margin-left: 0pt; text-indent: 0pt; margin-right: 0pt; width: 100%; margin-bottom: 10pt">
      <div>
        <div style="text-align: left">

        </div>
      </div>
      <div style="page-break-after: always">
        <div style="font-family: Times New Roman; font-size: 10pt; text-align: center">
          2
        </div>
        <div style="text-align: center">
          <hr style="color: black; height: 1.5pt">

        </div>
      </div>
      <div>
        <div style="text-align: right">

        </div>
      </div>
    </div>
    <p>

    </p>
    <p style="text-align: center">
      <font style="font-family: Times New Roman; font-size: 10pt"><b>SIGNATURE</b></font>
    </p>
    <p style="font-family: Times New Roman; text-indent: 30.0px; font-size: 10pt">
      <font style="font-family: Times New Roman; font-size: 10pt">Pursuant to
      the requirements of the Securities Exchange Act of 1934, the Registrant
      has duly caused this report to be signed</font> <font style="font-family: Times New Roman; font-size: 10pt">on
      its behalf by the undersigned hereunto duly authorized.</font>
    </p>
    <p>
      <br>

    </p>
    <div style="text-align:left">
    <table style="font-family: Times New Roman; font-size: 10pt; width: 100%; margin-bottom: 10.0px" cellspacing="0">
      <tr>
        <td style="width: 5%">

        </td>
        <td style="width: 45%">

        </td>
        <td valign="top" style="text-align: left; padding-left: 0.0px" colspan="2">
          <p style="margin-top: 0px; margin-bottom: 0px">
            <b>CELLDEX THERAPEUTICS, INC.</b>
          </p>
        </td>
      </tr>
      <tr>
        <td style="width: 5%">

        </td>
        <td style="width: 45%">

        </td>
        <td valign="top" style="text-align: left; padding-left: 0.0px" colspan="2">
          <p style="margin-top: 0px; margin-bottom: 0px">
            &#160;
          </p>
        </td>
      </tr>
      <tr>
        <td style="width: 5%">

        </td>
        <td style="width: 45%">

        </td>
        <td colspan="2">
          &#160;
        </td>
      </tr>
      <tr>
        <td valign="top" style="padding-bottom: 2.0px; width: 5%; text-align: left; padding-left: 0.0px">
          <p style="margin-top: 0px; margin-bottom: 0px">
            Date:
          </p>
        </td>
        <td valign="top" style="padding-bottom: 2.0px; width: 45%; text-align: left; padding-left: 0.0px">
          September 4, 2009
        </td>
        <td valign="top" style="padding-bottom: 2.0px; width: 4%; text-align: left; padding-left: 0.0px">
          By:
        </td>
        <td valign="top" style="width: 46%; text-align: left; border-bottom: solid black 1.0pt; padding-left: 0.0px">
          <p style="margin-top: 0px; margin-bottom: 0px">
            /s/ Avery W. Catlin
          </p>
        </td>
      </tr>
      <tr>
        <td style="width: 5%">

        </td>
        <td style="width: 45%">

        </td>
        <td style="width: 4%">

        </td>
        <td valign="top" style="width: 46%; text-align: left; padding-left: 0.0px">
          <p style="margin-top: 0px; margin-bottom: 0px">
            Avery W. Catlin
          </p>
        </td>
      </tr>
      <tr>
        <td style="width: 5%">

        </td>
        <td style="width: 45%">

        </td>
        <td style="width: 4%">

        </td>
        <td valign="top" style="width: 46%; text-align: left; padding-left: 0.0px">
          <p style="margin-top: 0px; margin-bottom: 0px">
            Title: Senior Vice President and
          </p>
        </td>
      </tr>
      <tr>
        <td style="width: 5%">

        </td>
        <td style="width: 45%">

        </td>
        <td style="width: 4%">

        </td>
        <td valign="top" style="width: 46%; text-align: left; padding-left: 0.0px">
          <p style="margin-top: 0px; margin-bottom: 0px">
            Chief Financial Officer
          </p>
        </td>
      </tr>
    </table>
    </div>
    <div style="margin-left: 0pt; text-indent: 0pt; margin-right: 0pt; width: 100%; margin-bottom: 10pt">
      <div>
        <div style="text-align: left">

        </div>
      </div>
      <div style="page-break-after: always">
        <div style="font-family: Times New Roman; font-size: 10pt; text-align: center">
          3
        </div>
        <div style="text-align: center">
          <hr style="color: black; height: 1.5pt">

        </div>
      </div>
      <div>
        <div style="text-align: right">

        </div>
      </div>
    </div>
    <p>

    </p>
    <p style="text-align: center">
      <b>EXHIBIT INDEX</b>
    </p>
    <p style="text-align: left">

    </p>
    <div style="text-align:left">
    <table style="font-family: Times New Roman; font-size: 10pt; width: 100%; margin-bottom: 10.0px" cellspacing="0">
      <tr>
        <td valign="middle" style="width: 12%; text-align: center; border-bottom: solid black 1.0pt; padding-left: 0.0px">
          <p style="margin-top: 0px; margin-bottom: 0px">
            <b>Exhibit</b>
          </p>
        </td>
        <td valign="middle" style="padding-bottom: 2.0px; width: 3%; text-align: left; padding-left: 0.0px">
          &#160;
        </td>
        <td valign="middle" style="width: 85%; text-align: left; border-bottom: solid black 1.0pt; padding-left: 0.0px">
          <p style="margin-top: 0px; margin-bottom: 0px">
            <b>Description</b>
          </p>
        </td>
      </tr>
      <tr>
        <td valign="top" style="width: 12%; text-align: left; padding-left: 0.0px">
          <p style="margin-top: 0px; margin-bottom: 0px">
            Exhibit 99.1
          </p>
        </td>
        <td style="width: 3%">

        </td>
        <td valign="top" style="width: 85%; text-align: left; padding-left: 0.0px">
          <p style="margin-top: 0px; margin-bottom: 0px">
            Press release issued by Celldex Therapeutics, Inc. announcing
            appointment of Larry Ellberger as Chairman of the Board.
          </p>
        </td>
      </tr>
    </table>
    </div>
    <p style="text-align: left">

    </p>
    <p style="text-align: center">
      4
    </p>
    <p style="text-align: center">

    </p>
    <p>

    </p>
  </body>
</html>
<!--<!DOCTYPE html
     PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN"
     "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd">-->
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>a6043347ex99_1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<html>
  <head>
    <title></title>
<!--Copyright 2009 Business Wire, a Berkshire Hathaway company.-->
<!--All rights reserved www.businesswire.com-->
  </head>
  <body style="font-family: Times New Roman; font-size: 8pt">
    <p style="text-align: right">
      <b>Exhibit 99.1</b>
    </p>
    <p style="text-align: center">
      <font style="font-family: Times New Roman; font-size: 12pt"><b>Celldex
      Therapeutics Announces Appointment of Larry Ellberger as Chairman of the
      Board</b></font>
    </p>
    <p>
      NEEDHAM, Mass.--(BUSINESS WIRE)--September 4, 2009--Celldex
      Therapeutics, Inc. (NASDAQ: CLDX) announced today that Larry Ellberger
      has been appointed Chairman of the Board of Directors, effective
      September 3, 2009. Mr. Ellberger has been an independent member of the
      Celldex Board of Directors since the merger in March 2008 between
      Celldex and AVANT Immunotherapeutics, Inc., and was a member of the
      AVANT Board since 2003. During his 30 years in the pharmaceutical and
      biotechnology industries, Mr. Ellberger had served as Board member and
      Chief Executive Officer of PDI, Inc., Chairman of the Board of Omrix
      Biopharmaceuticals, Inc. (which was purchased by Johnson &amp; Johnson in
      2008), as well as held senior executive positions at W.R. Grace &amp; Co.,
      American Cyanamid Company and Powderject Ltd. In addition to his current
      position as Founding Partner of HVA, a healthcare transaction advisory
      firm, Mr. Ellberger is a Director of TransPharma Medical Ltd. and the
      Jewish Children&#8217;s Museum.
    </p>
    <p>
      Charles R. Schaller will remain on the board as a director for the
      remainder of his term. &#8220;Chuck has provided Celldex with tremendous
      leadership over the years as its Chairman and we look forward to his
      continued guidance as a member of our board,&#8221; said Anthony Marucci,
      President and Chief Executive Officer of Celldex. &#8220;We welcome Larry in
      his new role as Chairman. As a board member, Larry has been deeply
      involved in the recent growth and success of Celldex. His experience
      within our industry will be critical as we advance our product
      portfolio,&#8221; continued Mr. Marucci.
    </p>
    <p>
      Mr. Ellberger will remain as a member of the Audit Committee of the
      Board of Directors, with George Elston becoming Chairman of the Audit
      Committee as of September 3, 2009.
    </p>
    <div style="margin-left: 0pt; text-indent: 0pt; width: 100%; margin-right: 0pt; margin-bottom: 10pt">
      <div>
        <div style="text-align: left">

        </div>
      </div>
      <div style="page-break-after: always">
        <div style="text-align: center">

        </div>
        <div style="text-align: center">
          <hr style="color: black; height: 1.5pt">

        </div>
      </div>
      <div>
        <div style="text-align: right">

        </div>
      </div>
    </div>
    <p>
      <b>About Celldex Therapeutics, Inc.</b>
    </p>
    <p>
      Celldex Therapeutics is an integrated biopharmaceutical company that
      applies its comprehensive Precision Targeted Immunotherapy Platform to
      generate a pipeline of candidates to treat cancer and other
      difficult-to-treat diseases. Celldex&#8217;s immunotherapy platform includes a
      complementary portfolio of monoclonal antibodies, antibody-targeted
      vaccines and immunomodulators to create novel disease-specific drug
      candidates. For more information, please visit <u>http://www.celldextherapeutics.com</u>.
    </p>
    <p>
      <i><b>Safe Harbor Statement Under the Private Securities Litigation
      Reform Act of 1995:</b></i> <i>This release contains ``forward-looking
      statements'' made pursuant to the safe harbor provisions of the Private
      Securities Litigation Reform Act of 1995,&#160;including those related to&#160;the
      Company's strategic&#160;focus and the future development&#160;and
      commercialization of our programs and products. Forward-looking
      statements reflect management's current knowledge, assumptions, judgment
      and expectations regarding future performance or events. Although
      management believes that the expectations reflected in such statements
      are reasonable, they give no assurance that such expectations will prove
      to be correct and you should be aware that actual results could differ
      materially from those contained in the forward-looking statements.
      Forward-looking statements are subject to a number of risks and
      uncertainties, including, but not limited to, our ability to close the
      merger of our wholly-owned subsidiary with CuraGen Corporation; the
      successful integration of the businesses, multiple technologies and
      programs of CuraGen and Celldex;&#160;our ability to&#160;adapt APC Targeting
      Technology<sup>TM</sup> to develop new, safe and effective vaccines
      against oncology and infectious disease indications;&#160;our ability to
      successfully complete product research and further development of our
      programs; the&#160;uncertainties inherent in clinical testing; our ability to
      manage research and development efforts for multiple products at varying
      stages of development; Pfizer&#8217;s and our strategy and business plans
      concerning the continued development and commercialization of CDX-110;
      the timing, cost and uncertainty of obtaining regulatory approvals; the
      failure of the market for the Company's&#160;programs to continue to develop;
      the inability to obtain additional capital; the inability to protect the
      Company's intellectual property; the loss of any executive officers or
      key personnel or consultants; competition; changes in the regulatory
      landscape or the imposition of regulations that affect the Company's
      products; and other risks detailed from time to time in the Company's
      filings with the Securities and Exchange Commission, including the
      Company's Form 10-K for the fiscal year ended&#160;December 31, 2008,
      and&#160;its&#160;Forms 10-Q and 8-K</i>.
    </p>
    <p>
      CONTACT:<br>Celldex Therapeutics, Inc.<br>Avery W. Catlin, 781-433-0771<br>Chief
      Financial Officer<br><u>IR@celldextherapeutics.com</u><br>or<br><u>For
      Media:</u><br>BMC Communications Group<br>Matthew Driscoll, 212-477-9007
      x20<br><u>mdriscoll@bmccommunications.com</u>
    </p>
  </body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
